New hope for targeted breast cancer treatment before surgery
Disease control
Not yet recruiting
This study is testing if adding a new drug called inavolisib to standard pre-surgery treatments works better for people with a specific type of early-stage, HER2-positive breast cancer that has a PIK3CA gene mutation. About 164 participants will be randomly assigned to receive th…
Phase: PHASE2 • Sponsor: Zhimin Shao • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC